- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07940192
Phenotype of Alcohol-Related Nutritional Sensory Neuronopathies and Comparison With Dysimmune and Paraneoplastic Forms (NNS-OH)
Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: +33 04 77 12 78 05
- E-post: j.philippe.camdessanche@chuse.fr
Studiesteder
-
-
-
Brest, Frankrike, 29200
- CHU de Brest
-
Ta kontakt med:
- Jean-Baptiste NOURY
- Telefonnummer: +33 02 98 22 33 33
- E-post: jean-baptiste.noury@chu-brest.fr
-
Grenoble, Frankrike, 38500
- CHU de Grenoble
-
Ta kontakt med:
- Martial Mallaret
- Telefonnummer: +33 04 76 76 75 75
- E-post: MMallaret1@chu-grenoble.fr
-
Lille, Frankrike, 59000
- CHU de Lille
-
Ta kontakt med:
- Céline TARD, Dr
- Telefonnummer: +33 03 20 44 59 62
- E-post: CELINE.TARD@CHRU-LILLE.FR
-
Limoges, Frankrike, 87000
- CHU de Limoges
-
Ta kontakt med:
- Laurent MAGY
- Telefonnummer: +33 05 55 05 55 55
- E-post: Laurent.Magy@chu-limoges.fr
-
Montpellier, Frankrike, 34090
- CHU de Montpellier
-
Ta kontakt med:
- Guillaume TAIEB
- Telefonnummer: +33 04 67 33 67 33
- E-post: g-taieb@chu-montpellier.fr
-
Nantes, Frankrike, 44093
- CHU de Nantes
-
Ta kontakt med:
- Yann PEREON
- Telefonnummer: +33 02 40 08 33 33
- E-post: Yann.Pereon@univ-nantes.fr
-
Reims, Frankrike, 51100
- CHU de REIMS
-
Ta kontakt med:
- Maxime Kirchhofer, Dr
- Telefonnummer: +33 03 26 78 78 78.
- E-post: mkirchhofer@chu-reims.fr
-
-
France
-
Bordeaux, France, Frankrike, 33000
- CHU de Bordeaux
-
Ta kontakt med:
- Guilhem SOLE, Dr
- Telefonnummer: +33 05.56.79.56.79
- E-post: guilhem.sole@chu-bordeaux.fr
-
Créteil, France, Frankrike, 94000
- CHU Henri-Mondor
-
Ta kontakt med:
- Thierry GENDRE, Dr
- Telefonnummer: + 33 01 49 81 21 11
- E-post: thierry.gendre@aphp.fr
-
Garches, France, Frankrike, 92380
- AP-HP Hôpital Raymond-Poincaré
-
Ta kontakt med:
- Edouard BERLING, Dr
- Telefonnummer: + 33 01 47 10 79 00
- E-post: edouard.berling@aphp.fr
-
Le Kremlin-Bicêtre, France, Frankrike, 94270
- CHU de Bicetre
-
Ta kontakt med:
- Guillemette BEAUDONNET, Dr
- Telefonnummer: + 33 01 45 21 21 21
- E-post: guillemette.beaudonnet@aphp.fr
-
Marseille, France, Frankrike, 13005
- AP-HM Hôpital de la Timone
-
Ta kontakt med:
- Emilien DELMONT, Dr
- Telefonnummer: +33 04 91 38 56 65
- E-post: Emilien.DELMONT@ap-hm.fr
-
Paris, France, Frankrike, 75013
- AP-HP Hôpital Pitié-Salpêtrière
-
Ta kontakt med:
- Thierry MAISONOBE, Dr
- Telefonnummer: +33 01 42 16 00 00
- E-post: thierry.maisonobe@aphp.fr
-
Saint-Etienne, France, Frankrike, 42055
- CHU de Saint-Etienne
-
Ta kontakt med:
- Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: + 33 04 77 12 78 05
- E-post: j.philippe.camdessanche@chuse.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients monitored in a neurology department for their sensory neuropathies
Beskrivelse
Inclusion Criteria :
- Age ≥ 18 years.
- Probable sensory neuronopathy according to the diagnostic criteria of Camdessanché et al.
- Acute or subacute onset (0-6 months).
- One of the following aetiologies: Alcohol-related nutritional SNN: chronic alcohol misuse (>100 g/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded. The minimum work-up includes an immune laboratory assessment including serum anti-neuronal antibodies, lumbar puncture, and thoraco-abdominal imaging. Dysimmune SNN: associated with Sjögren's syndrome, lupus, primary biliary cholangitis, anti-FGFR3 antibodies, or anti-AGO antibodies. Paraneoplastic SNN: associated with anti-Hu or anti-CV2/CRMP5 antibodies.
Exclusion Criteria :
- Exposure to platinum salts before the onset of sensory neuronopathy.
- Known hereditary neuropathy.
- Patient under guardianship or curatorship (tutelle or curatelle).
- Patient objection to the use of their data for the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Alcohol-related nutritional sensory neuronopathy
Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol. |
|
Dysimmune sensory neuronopathy
Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies. |
|
Paraneoplastic sensory neuronopathy
Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Demographic and disease onset characteristics
Tidsramme: from july 2006 to april 2027
|
Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records. |
from july 2006 to april 2027
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Jean-Phillippe CAMDESSANCHE, PUPH, CHU de Saint-Etienne
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IRBN 154-2026/CHUSTE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .